Referencias:

• Asa, S.L., Ezzat, S., The cytogenesis and pathogenesis of pituitary adenomas (1998) Endocr Rev, 19, pp. 798-827
• Ezzat, S., Asa, S.L., Mechanisms of disease: The pathogenesis of pituitary tumors (2006) Nat Clin Pract Endocrinol Metab, 2, pp. 220-230
• Arzt, E., Pereda, M.P., Castro, C.P., Pagotto, U., Renner, U., Stalla, G.K., Pathophysiological role of the cytokine network in the anterior pituitary gland (1999) Front Neuroendocrinol, 20, pp. 71-95
• Arzt, E., gp130 cytokine signaling in the pituitary gland: A paradigm for cytokine-neuroendocrine pathways (2001) J Clin Invest, 108, pp. 1729-1733
• Clayton, R.N., Farrell, W.E., Pituitary tumour clonality revisited (2004) Front Horm Res, 32, pp. 186-204
• Alexander, J.M., Biller, B.M., Bikkal, H., Zervas, N.T., Arnold, A., Klibanski, A., Clinically nonfunctioning pituitary tumors are monoclonal in origin (1990) J Clin Invest, 86, pp. 336-340
• Kovacs, K., Horvath, E., Vidal, S., Classification of pituitary adenomas (2001) J Neurooncol, 54, pp. 121-127
• Yu, R., Melmed, S., Oncogene activation in pituitary tumors (2001) Brain Path, 11, pp. 328-341
• Melmed, S., Update in pituitary disease (2008) J Clin Endocrinol Metab, 93, pp. 331-338
• Castro, C.P., Giacomini, D., Nagashima, A.C., Onofri, C., Graciarena, M., Kobayashi, K., Paez-Pereda, M., Arzt, E., Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of pituitary lactosomatotrophic GH3 cells (2003) Endocrinology, 144, pp. 693-700
• Carbia-Nagashima, A., Gerez, J., Perez-Castro, C., Paez-Pereda, M., Silberstein, S., Stalla, G.K., Holsboer, F., Arzt, E., RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-lalpha during hypoxia (2007) Cell, 131, pp. 309-323
• Renner, U., Lohrer, P., Schaaf, L., Feirer, M., Schmitt, K., Onofri, C., Arzt, E., Stalla, G.K., Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells (2002) Endocrinology, 143, pp. 3759-3765
• Gloddek, J., Pagotto, U., Paez Pereda, M., Arzt, E., Stalla, G.K., Renner, U., Pituitary adenylate cy-clase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells (1999) J Endocrinol, 160, pp. 483-490
• Onofri, C., Theodoropoulou, M., Losa, M., Uhl, E., Lange, M., Arzt, E., Stalla, G.K., Renner, U., Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: Detection of a non-en-dothelial function of VEGF in pituitary tumours (2006) J Endocrinol, 191, pp. 249-261
• Paez-Pereda, M., Giacomini, D., Refojo, D., Nagashima, A.C., Hopfner, U., Grubler, Y., Chervin, A., Arzt, E., Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk (2003) Proc Natl Acad Sci USA, 100, pp. 1034-1039
• Schmierer, B., Hill, C.S., TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility (2007) Nat Rev Mol Cell Biol, 8, pp. 970-982
• Massague, J., TGF-beta signal transduction (1998) Annu Rev Biochem, 67, pp. 753-791
• Massague, J., How cells read TGF-beta signals (2000) Nat Rev Mol Cell Biol, 1, pp. 169-178
• Hentges, S., Sarkar, D.K., Transforming growth factor-beta regulation of estradiol-induced prolactinomas (2001) Front Neuroendocrinol, 22, pp. 340-363
• Shi, Y., Massague, J., Mechanisms of TGF-beta signalingfrom cell membrane to the nucleus (2003) Cell, 113, pp. 685-700
• Massague, J., Chen, Y.G., Controlling TGF-beta signaling (2000) Genes Dev, 14, pp. 627-644
• Bellusci, S., Henderson, R., Winnier, G., Oikawa, T., Hogan, B.L., Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis (1996) Development, 122, pp. 1693-1702
• Hogan, B.L., Blessing, M., Winnier, G.E., Suzuki, N., Jones, C.M., Growth factors in development: The role of TGF-beta related polypeptide signalling molecules in embryogenesis (1994) Dev Suppl, pp. 53-60
• Winnier, G., Blessing, M., Labosky, P.A., Hogan, B.L., Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse (1995) Genes Dev, 9, pp. 2105-2116
• Wilson, P.A., Hemmati-Brivanlou, A., Induction of epidermis and inhibition of neural fate by Bmp-4 (1995) Nature, 376, pp. 331-333
• Harland, R.M., Neural induction in Xenopus (1994) Curr Opin Genet Dev, 4, pp. 543-549
• Sasai, Y., Lu, B., Steinbeisser, H., De Robertis, E.M., Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in Xenopus (1995) Nature, 377, p. 757
• Lamb, T.M., Knecht, A.K., Smith, W.C., Stachel, S.E., Economides, A.N., Stahl, N., Yancopolous, G.D., Harland, R.M., Neural induction by the secreted polypeptide noggin (1993) Science, 262, pp. 713-718
• Rossi, J.M., Dunn, N.R., Hogan, B.L., Zaret, K.S., Distinct mesodermal signals, including BMPs from septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm (2001) Genes Dev, 15, pp. 1998-2009
• Dudley, A.T., Lyons, K.M., Robertson, E.J., A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye (1995) Genes Dev, 9, pp. 2795-2807
• Roberts, D.J., Johnson, R.L., Burke, A.C., Nelson, C.E., Morgan, B.A., Tabin, C., Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes during induction and regional-ization of the chick hindgut (1995) Development, 121, pp. 3163-3174
• Giacomini, D., Paez-Pereda, M., Theodoropoulou, M., Gerez, J., Nagashima, A.C., Chervin, A., Berner, S., Arzt, E., Bone morphogenetic pro-tein-4 control of pituitary pathophysiology (2006) Front Horm Res, 35, pp. 22-31
• Takeda, M., Otsuka, F., Suzuki, J., Kishida, M., Ogura, T., Tamiya, T., Makino, H., Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas (2003) Biochem Biophys Res Commun, 306, pp. 812-818
• Kawabata, M., Imamura, T., Miyazono, K., Signal transduction by bone morphogenetic proteins (1998) Cytokine Growth Factor Rev, 9, pp. 49-61
• Chen, C.R., Kang, Y., Massague, J., Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program (2001) Proc Natl Acad Sci USA, 98, pp. 992-999
• Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., Miyazono, K., Kato, M., c-myc is a downstream target of the Smad pathway (2002) J Biol Chem, 277, pp. 854-861
• Nudi, M., Ouimette, J.F., Drouin, J., Bone mor-phogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity (2005) Mol Endocrinol, 19, pp. 1329-1342
• Morris, D., Grossman, A., The medical management of Cushing's syndrome (2002) Ann NY Acad Sci, 970, pp. 119-133
• Nieman, L.K., Medical therapy of Cushing's disease (2002) Pituitary, 5, pp. 77-82
• De Herder, W.W., Lamberts, S.W., Octapeptide somatostatin-analogue therapy of Cushing's syndrome (1999) Postgrad Med J, 75, pp. 65-66
• Boscaro, M., Barzon, L., Fallo, F., Sonino, N., Cushing's syndrome (2001) Lancet, 357, pp. 783-791
• Merino, R., Hurle, J.M., The molecular basis of retinoid action in tumors (2003) Trends Mol Med, 9, pp. 509-511
• Lotan, R., Retinoids in cancer chemopreven-tion (1996) Faseb J, 10, pp. 1031-1039
• Kurie, J.M., The biologic basis for the use of retinoids in cancer prevention and treatment (1999) Curr Opin Oncol, 11, pp. 497-502
• Kurie, J.M., Hong, W.K., Retinoids as antitumor agents: A new age of biological therapy (1999) Cancer J Sci Am, 5, pp. 150-151
• Kang, H.J., Song, M.R., Lee, S.K., Shin, E.C., Choi, Y.H., Kim, S.J., Lee, J.W., Lee, M.O., Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: A possible mechanism for the inhibition of apoptosis by retinoic acid (2000) Exp Cell Res, 256, pp. 545-554
• Fanjul, A., Dawson, M.I., Hobbs, P.D., Jong, L., Cameron, J.F., Harlev, E., Graupner, G., Pfahl, M., A new class of retinoids with selective inhibition of AP-1 inhibits proliferation (1994) Nature, 372, pp. 107-111
• Philips, A., Lesage, S., Gingras, R., Maira, M.H., Gauthier, Y., Hugo, P., Drouin, J., Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells (1997) Mol Cell Biol, 17, pp. 5946-5951
• Maira, M., Martens, C., Philips, A., Drouin, J., Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation (1999) Mol Cell Biol, 19, pp. 7549-7557
• Kovalovsky, D., Refojo, D., Liberman, A.C., Hochbaum, D., Pereda, M.P., Coso, O.A., Stalla, G.K., Arzt, E., Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: Involvement of calcium, protein kinase A, and MAPK pathways (2002) Mol Endocrinol, 16, pp. 1638-1651
• Páez-Pereda, M., Kovalovsky, D., Hopfner, U., Theodoropoulou, M., Pagotto, U., Uhl, E., Losa, M., Stalla, G., Retinoic acid prevents experimental Cushing syndrome (2001) J Clin Invest, 108, pp. 1123-1131
• Ling, G.V., Stabenfeldt, G.H., Comer, K.M., Cribble, D.H., Schechter, R.D., Canine hyperadreno-corticism: Pretreatment clinical and laboratory evaluation of 117 cases (1979) J Am Vet Med Assoc, 174, pp. 1211-1215
• Castillo, V., Giacomini, D., Paez-Pereda, M., Stalla, J., Labeur, M., Theodoropoulou, M., Holsboer, F., Arzt, E., Retinoic acid as a novel medical therapy for Cushing's disease in dogs (2006) Endocrinology, 147, pp. 4438-4444
• Giacomini, D., Paez-Pereda, M., Theodoropoulou, M., Labeur, M., Refojo, D., Gerez, J., Chervin, A., Arzt, E., Bone morphogenetic protein-4 inhibits corticotroph tumor cells: Involvement in the retinoic acid inhibitory action (2006) Endocrinology, 147, pp. 247-256
• Yamamoto, T., Saatcioglu, F., Matsuda, T., Crosstalk between bone morphogenic proteins and estrogen receptor signaling (2002) Endocrinology, 143, pp. 2635-2642
• Matsuda, T., Yamamoto, T., Muraguchi, A., Saatcioglu, F., Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3 (2001) J Biol Chem, 276, pp. 42908-42914

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------